The results of our investigation show that pola-related analytes have generally similar plasma/serum PK when given in combination with rituximab- and obinutuzumab-containing therapies, and between patients with mixed subtypes of B-NHL or DLBCL, and between treatment-naïve versus R/R status. This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.